Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20532 | 0.83 | — | — | |
| SCHEMBL260003 | 0.80 | — | — | |
| SCHEMBL40788 | 0.80 | — | — | |
| SCHEMBL112370 | 0.80 | CA1 (0.38) | ALDH1A1 | |
| SCHEMBL21237759 | 0.80 | CA1 (0.38) | ALDH1A1 | |
| SCHEMBL566961 | 0.80 | — | — | |
| Cyclohexane SCHEMBL15212796 | 0.80 | CA1 (0.38) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1162671 | 0.80 | — | — | |
| SCHEMBL1472301 | 0.80 | CA1 (0.38) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8078551 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394913-B | Synthetic method of oxime ether derivative | 山东农业大学 | 2023-02-03 | — | — | CN | claimed |
| EP-2424862-B1 | PROCESS FOR PREPARING SUBSTITUTED ISOXAZOLINE COMPOUNDS AND THEIR PRECURSORS | BASF SE (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8853410-B2 | Process for preparing substituted isoxazoline compounds and their precursors | BASF SE (DE) | 2014-10-07 | — | — | US | disclosed |
| EP-2418197-B1 | PROCESS FOR PRODUCING 3-(2-CYANO-1-PROPENYL)-2,2- DIMETHYLCYCLOPROPANECARBOXYLIC ACID OR SALT THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20120059171-A1 | Process for Preparing Substituted Isoxazoline Compounds and Their Precursors | BASF SE (DE) | 2012-03-08 | — | — | US | disclosed |
| EP-2424862-A1 | PROCESS FOR PREPARING SUBSTITUTED ISOXAZOLINE COMPOUNDS AND THEIR PRECURSORS | BASF SE (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125130-A1 | PROCESS FOR PREPARING SUBSTITUTED ISOXAZOLINE COMPOUNDS AND THEIR PRECURSORS | BASF SE (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059171-A1 | Process for Preparing Substituted Isoxazoline Compounds and Their Precursors | CYP4X1, CYP3A7, CYP1B1 | ALDH1A1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.